Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2010 1
2011 1
2012 1
2013 2
2014 1
2015 2
2017 3
2018 2
2019 3
2020 4
2021 2
2022 5
2023 4
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

28 results

Results by year

Filters applied: . Clear all
Page 1
Single-cell multiomics reveals increased plasticity, resistant populations, and stem-cell-like blasts in KMT2A-rearranged leukemia.
Chen C, Yu W, Alikarami F, Qiu Q, Chen CH, Flournoy J, Gao P, Uzun Y, Fang L, Davenport JW, Hu Y, Zhu Q, Wang K, Libbrecht C, Felmeister A, Rozich I, Ding YY, Hunger SP, Felix CA, Wu H, Brown PA, Guest EM, Barrett DM, Bernt KM, Tan K. Chen C, et al. Among authors: guest em. Blood. 2022 Apr 7;139(14):2198-2211. doi: 10.1182/blood.2021013442. Blood. 2022. PMID: 34864916 Free PMC article.
Gemtuzumab Ozogamicin Improves Event-Free Survival and Reduces Relapse in Pediatric KMT2A-Rearranged AML: Results From the Phase III Children's Oncology Group Trial AAML0531.
Pollard JA, Guest E, Alonzo TA, Gerbing RB, Loken MR, Brodersen LE, Kolb EA, Aplenc R, Meshinchi S, Raimondi SC, Hirsch B, Gamis AS. Pollard JA, et al. Among authors: guest e. J Clin Oncol. 2021 Oct 1;39(28):3149-3160. doi: 10.1200/JCO.20.03048. Epub 2021 May 28. J Clin Oncol. 2021. PMID: 34048275 Free PMC article. Clinical Trial.
Measurable Residual Disease and Fusion Partner Independently Predict Survival and Relapse Risk in Childhood KMT2A-Rearranged Acute Myeloid Leukemia: A Study by the International Berlin-Frankfurt-Münster Study Group.
van Weelderen RE, Klein K, Harrison CJ, Jiang Y, Abrahamsson J, Arad-Cohen N, Bart-Delabesse E, Buldini B, De Moerloose B, Dworzak MN, Elitzur S, Fernández Navarro JM, Gerbing RB, Goemans BF, de Groot-Kruseman HA, Guest E, Ha SY, Hasle H, Kelaidi C, Lapillonne H, Leverger G, Locatelli F, Masetti R, Miyamura T, Norén-Nyström U, Polychronopoulou S, Rasche M, Rubnitz JE, Stary J, Tierens A, Tomizawa D, Zwaan CM, Kaspers GJL. van Weelderen RE, et al. Among authors: guest e. J Clin Oncol. 2023 Jun 1;41(16):2963-2974. doi: 10.1200/JCO.22.02120. Epub 2023 Mar 30. J Clin Oncol. 2023. PMID: 36996387 Free PMC article.
Childhood cancer for the primary care physician.
Radhi M, Fulbright JM, Ginn KF, Guest EM. Radhi M, et al. Among authors: guest em. Prim Care. 2015 Mar;42(1):43-55. doi: 10.1016/j.pop.2014.09.006. Epub 2014 Nov 11. Prim Care. 2015. PMID: 25634704 Review.
Preclinical efficacy of azacitidine and venetoclax for infant KMT2A-rearranged acute lymphoblastic leukemia reveals a new therapeutic strategy.
Cheung LC, Aya-Bonilla C, Cruickshank MN, Chiu SK, Kuek V, Anderson D, Chua GA, Singh S, Oommen J, Ferrari E, Hughes AM, Ford J, Kunold E, Hesselman MC, Post F, Faulk KE, Breese EH, Guest EM, Brown PA, Loh ML, Lock RB, Kees UR, Jafari R, Malinge S, Kotecha RS. Cheung LC, et al. Among authors: guest em. Leukemia. 2023 Jan;37(1):61-71. doi: 10.1038/s41375-022-01746-3. Epub 2022 Nov 15. Leukemia. 2023. PMID: 36380143 Free PMC article.
Minimal residual disease predicts outcomes in KMT2A-rearranged but not KMT2A-germline infant acute lymphoblastic leukemia: Report from Children's Oncology Group study AALL0631.
Faulk KE, Kairalla JA, Dreyer ZE, Carroll AJ, Heerema NA, Devidas M, Carroll WL, Raetz EA, Loh ML, Hunger SP, Borowitz M, Wang C, Guest E, Brown PA. Faulk KE, et al. Among authors: guest e. Pediatr Blood Cancer. 2023 May 31:e30467. doi: 10.1002/pbc.30467. Online ahead of print. Pediatr Blood Cancer. 2023. PMID: 37259259
Racial and ethnic disparities in childhood and young adult acute lymphocytic leukaemia: secondary analyses of eight Children's Oncology Group cohort trials.
Gupta S, Dai Y, Chen Z, Winestone LE, Teachey DT, Bona K, Aplenc R, Rabin KR, Zweidler-McKay P, Carroll AJ, Heerema NA, Gastier-Foster J, Borowitz MJ, Wood BL, Maloney KW, Mattano LA Jr, Larsen EC, Angiolillo AL, Burke MJ, Salzer WL, Winter SS, Brown PA, Guest EM, Dunsmore KP, Kairalla JA, Winick NJ, Carroll WL, Raetz EA, Hunger SP, Loh ML, Devidas M. Gupta S, et al. Among authors: guest em. Lancet Haematol. 2023 Feb;10(2):e129-e141. doi: 10.1016/S2352-3026(22)00371-4. Lancet Haematol. 2023. PMID: 36725118 Free PMC article.
Real-world use of tisagenlecleucel in infant acute lymphoblastic leukemia.
Moskop A, Pommert L, Baggott C, Prabhu S, Pacenta HL, Phillips CL, Rossoff J, Stefanski HE, Talano JA, Margossian SP, Verneris MR, Myers GD, Karras NA, Brown PA, Qayed M, Hermiston ML, Satwani P, Krupski C, Keating AK, Wilcox R, Rabik CA, Fabrizio VA, Chinnabhandar V, Goksenin AY, Curran KJ, Mackall CL, Laetsch TW, Guest EM, Breese EH, Schultz LM. Moskop A, et al. Among authors: guest em. Blood Adv. 2022 Jul 26;6(14):4251-4255. doi: 10.1182/bloodadvances.2021006393. Blood Adv. 2022. PMID: 35580324 Free PMC article.
28 results